Granted preliminary injunction restraining Professional Compounding Centers of America, Inc. "from acting directly or indirectly" to sell pentamidine or contract doctors, hospitals, or pharmacists to solicit orders for the drug. In a May 23 motion filed in Houston federal court, Lyphomed accused Professional Compounding Centers of "selling bulk pentamidine, without FDA approval, to pharmacies." A trial date will be scheduled "shortly after Sept. 1, 1989," the injunction states.
You may also be interested in...
The SEEK spin-out ConserV Bioscience is developing a broad-spectrum coronavirus vaccine, aiming to get ahead of the arrival of new strains of the virus.
The CEO of Biocon’s biosimilars subsidiary has unexpectedly departed the role. Management stresses there is no disruption to its "strategic intent", but COVID-19 has "dampened" the arm’s push to reach its aspirational $1bn revenue target by 2022.
CHF Solutions adds “CEO” to its president’s job title; Agilent VP of business development promoted to senior VP; Zimmer hires chief transformation officer; and more.